Richard C. Shelton, MD
Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, Alabama
Original Research
Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life
August 11, 2025
Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.
Original Research
Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study
August 6, 2025
Onfasprodil appeared to be effective and well-tolerated across all dosing regimens in patients with TRD and demonstrated rapid onset of action (24 hours) with evidence of antidepressant effects to...
Original Research
Adjunctive Pimavanserin and Sleep/Wakefulness in MDD
December 1, 2020
Adjunctive pimavanserin can reduce depressive symptoms and improve function in patients with major depression and inadequate antidepressant response. This analysis evaluated the effects of adjunctive pimavanserin on sleep/wakefulness disturbances.
Original Research
Utility of Combinatorial Pharmacogenomics in Depression
October 31, 2019
This study sought to ascertain the extent that pharmacogenetic testing can inform treatment decisions among patients with treatment-resistant depression whose medications are subject to gene-drug interactions—read the article to...
Original Research
Ziprasidone Augmentation of Escitalopram for Cognition
July 25, 2017
Cognitive deficits are common in depression, but studies suggest that cognitive dysfunction is difficult to treat with antidepressants. Can adding an atypical antipsychotic medication to antidepressant treatment help lessen...
